These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3470166)

  • 21. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the 4-quinolone enoxacin on plasma theophylline concentrations.
    Wijnands WJ; Vree TB; Van Herwaarden CL
    Pharm Weekbl Sci; 1986 Feb; 8(1):42-5. PubMed ID: 3457357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Penetration of enoxacin into human bronchial mucosa.
    Marlin GE; Braude PD; Whelan AJ; Somogyi AA
    Am Rev Respir Dis; 1986 Dec; 134(6):1209-12. PubMed ID: 3466562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Enoxacin concentration in human prostatic tissue].
    Yasumoto R; Kobayakawa H; Asakawa M
    Hinyokika Kiyo; 1986 Oct; 32(10):1471-3. PubMed ID: 2436463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of enoxacin into bronchial secretions.
    Fong IW; Vandenbroucke A; Simbul M
    Antimicrob Agents Chemother; 1987 May; 31(5):748-51. PubMed ID: 3475036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.
    Lecaillon JB; Dubois JP; Coppens H; Darragon T; Reumond G; Pozet N; Traeger J; Lambrey G
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):231-7. PubMed ID: 2253654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    Davies BI; Maesen FP; Teengs JP
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():83-9. PubMed ID: 6594325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of hydrochlorothiazide in relation to renal function.
    Niemeyer C; Hasenfuss G; Wais U; Knauf H; Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(5):661-5. PubMed ID: 6873147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.
    Munn S; Bailey RR; Begg E; Ebert R; Ferry DG
    N Z Med J; 1980 Apr; 91(658):289-91. PubMed ID: 6930006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diffusion, in the bronchial mucus, of enoxacin administered by oral route in man].
    Morel C; Vergnaud M; Malbruny B; Benard Y
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):781-4. PubMed ID: 3309815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between renal function and disposition of oral cefixime.
    Dhib M; Moulin B; Leroy A; Hameau B; Godin M; Johannides R; Fillastre JP
    Eur J Clin Pharmacol; 1991; 41(6):579-83. PubMed ID: 1815970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone penetration of enoxacin in patients with and without osteomyelitis.
    Fong IW; Rittenhouse BR; Simbul M; Vandenbroucke AC
    Antimicrob Agents Chemother; 1988 Jun; 32(6):834-7. PubMed ID: 3166359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of caffeine elimination in man during co-administration of 4-quinolones.
    Stille W; Harder S; Mieke S; Beer C; Shah PM; Frech K; Staib AH
    J Antimicrob Chemother; 1987 Nov; 20(5):729-34. PubMed ID: 3480885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole in patients with impaired kidney function.
    Vree TB; Hekster YA; Damsma JE; van Dalen R; Hafkenscheid JC; Friesen WT
    Ther Drug Monit; 1981; 3(2):129-35. PubMed ID: 7268825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.